Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 1/20 | 0.66 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.49 |
| ▸ | AKT1 | P31749 | 6/20 | 0.46 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.44 |
| ▸ | LRRK2 | Q5S007 | 4/20 | 0.40 |
| ▸ | BRAF | P15056 | 1/20 | 0.39 |
| ▸ | TNNI3K | Q59H18 | 1/20 | 0.39 |
| ▸ | AURKA | O14965 | 1/20 | 0.38 |
| ▸ | JAK3 | P52333 | 3/20 | 0.36 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.36 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.36 |
| ▸ | CDK2 | P24941 | 1/20 | 0.36 |
| ▸ | CDK9 | P50750 | 1/20 | 0.36 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.36 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.36 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31329069 | 1.00 | CHEK1 (0.66) | CHEK1NOTUMAKT1TRPA1LRRK2 | |
| SCHEMBL23735452 | 0.81 | CHEK1 (0.48) | CHEK1NOTUMAKT1TRPA1LRRK2 | |
| SCHEMBL2323682 | 0.81 | CHEK1 (0.63) | CHEK1NOTUMAKT1TRPA1LRRK2 | |
| SCHEMBL153752 | 0.81 | CHEK1 (0.63) | CHEK1NOTUMAKT1TRPA1LRRK2 | |
| SCHEMBL2321413 | 0.79 | CHEK1 (0.61) | CHEK1NOTUMAKT1TRPA1LRRK2 | |
| SCHEMBL154600 | 0.79 | CHEK1 (0.61) | CHEK1NOTUMAKT1TRPA1BRAF | |
| SCHEMBL61206 | 0.79 | CHEK1 (1.00) | CHEK1NOTUMAKT1TRPA1LRRK2 | |
| SCHEMBL357993 | 0.79 | CHEK1 (0.61) | CHEK1NOTUMAKT1TRPA1BRAF | |
| SCHEMBL5019486 | 0.79 | CHEK1 (0.61) | CHEK1NOTUMAKT1TRPA1LRRK2 | |
| SCHEMBL21620551 | 0.79 | CHEK1 (0.47) | CHEK1NOTUMAKT1TRPA1LRRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 159 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250134869-A1 | Pyrrolo[2,3-d]pyrimidinyl, Pyrrolo[2,3-b]pyrazinyl and Pyrrolo[2,3-d]pyridinyl Acryla-mides | PFIZER INC (US) | 2025-05-01 | — | — | US | disclosed |
| US-12077533-B2 | Pyrrolo[2,3-d]pyrimidinyl, pyrrolo[2,3-b]pyrazinyl and pyrrolo[2,3-d]pyridinyl acrylamides | PFIZER INC. (US) | 2024-09-03 | — | — | US | disclosed |
| WO-2023238919-A1 | HYBRID TYPE COMPOUND OR SALT THEREOF | 渡部 良広 | 2023-12-14 | — | — | WO | disclosed |
| US-20230027361-A1 | METTL3 MODULATORS | ACCENT THERAPEUTICS, INC. (US) | 2023-01-26 | — | — | US | disclosed |
| US-20230027361-A1 | METTL3 MODULATORS | ACCENT THERAPEUTICS, INC. (US) | 2023-01-26 | — | — | US | disclosed |
| US-20230009153-A1 | PYRROLO[2,3-D]PYRIMIDINYL, PYRROLO[2,3-B]PYRAZINYL AND PYRROLO[2,3-D]PYRIDINYL ACRYLAMIDES | PFIZER INC. (US) | 2023-01-12 | — | — | US | disclosed |
| US-20230009153-A1 | PYRROLO[2,3-D]PYRIMIDINYL, PYRROLO[2,3-B]PYRAZINYL AND PYRROLO[2,3-D]PYRIDINYL ACRYLAMIDES | PFIZER INC. (US) | 2023-01-12 | — | — | US | disclosed |
| US-20220372040-A1 | METTL3 MODULATORS | ACCENT THERAPEUTICS, INC. (US) | 2022-11-24 | — | — | US | disclosed |
| US-20220372040-A1 | METTL3 MODULATORS | ACCENT THERAPEUTICS, INC. (US) | 2022-11-24 | — | — | US | disclosed |
| CN-115279756-A | METTL3 modulators | 埃克森特治疗公司 | 2022-11-01 | — | — | CN | disclosed |
| US-20040058922-A1 | Pyrrolo[2,3-d]pyrimidine compounds | PFIZER INC. | 2004-03-25 | — | — | US | disclosed |
| US-20030212273-A1 | Pyrrolo [2,3-D] pyrimidine compounds | PFIZER INC. | 2003-11-13 | — | — | US | disclosed |
| US-6635762-B1 | Protein tyrosine kinase or Janus Kinase 3 inhibitors; immunosuppressants | PFIZER INC. | 2003-10-21 | — | — | US | disclosed |
| US-6610847-B2 | Tyrosine kinase inhibitors; immunosuppressants | PFIZER INC. | 2003-08-26 | — | — | US | disclosed |
| US-20020019526-A1 | Pyrrolo[2,3-d]pyrimidine compounds | PFIZER INC. | 2002-02-14 | — | — | US | disclosed |
| EP-1087971-A1 | PYRROLO 2,3-d]PYRIMIDINE COMPOUNDS | Pfizer Products Inc. (US) | 2001-04-04 | — | — | EP | disclosed |
| EP-1087970-A1 | PYRROLO 2,3-d]PYRIMIDINE COMPOUNDS | Pfizer Products Inc. (US) | 2001-04-04 | — | — | EP | disclosed |
| WO-1999065909-A1 | PYRROLO[2,3-d]PYRIMIDINE COMPOUNDS | PFIZER PRODUCTS INC. (US) | 1999-12-23 | — | — | WO | disclosed |
| WO-1999065908-A1 | PYRROLO[2,3-d]PYRIMIDINE COMPOUNDS | PFIZER PRODUCTS INC. (US) | 1999-12-23 | — | — | WO | disclosed |
| US-4968686-A | DECREASED CYTOTOXICITY; CYTOMEGALO AND HERPEX SIMPLEX VIRUSES | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 1990-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230027361-A1 | METTL3 MODULATORS | METTL3, METTL16, METTL14 | CHEK1 3607/4885NOTUM 2694/4885AKT1 2722/4885 |
| US-12077533-B2 | Pyrrolo[2,3-d]pyrimidinyl, pyrrolo[2,3-b]pyrazinyl and pyrrolo[2,3-d]pyridinyl acrylamides | ACR, PKD2, PGA5 | CHEK1 718/4885NOTUM 2929/4885AKT1 3455/4885 |
| US-20040058922-A1 | Pyrrolo[2,3-d]pyrimidine compounds | JAK1, JAK3, JAK2 | CHEK1 403/4885NOTUM 3508/4885AKT1 595/4885 |
| US-20020019526-A1 | Pyrrolo[2,3-d]pyrimidine compounds | JAK1, JAK3, JAK2 | CHEK1 403/4885NOTUM 3508/4885AKT1 595/4885 |
| US-20220372040-A1 | METTL3 MODULATORS | METTL3, METTL16, METTL14 | CHEK1 3626/4885NOTUM 2560/4885AKT1 2850/4885 |
| US-20250134869-A1 | Pyrrolo[2,3-d]pyrimidinyl, Pyrrolo[2,3-b]pyrazinyl and Pyrrolo[2,3-d]pyridinyl Acryla-mides | JAK2, JAK3, JAK1 | CHEK1 339/4885NOTUM 3663/4885AKT1 690/4885 |
| US-20230009153-A1 | PYRROLO[2,3-D]PYRIMIDINYL, PYRROLO[2,3-B]PYRAZINYL AND PYRROLO[2,3-D]PYRIDINYL ACRYLAMIDES | JAK2, JAK3, JAK1 | CHEK1 320/4885NOTUM 3744/4885AKT1 667/4885 |
| US-20030212273-A1 | Pyrrolo [2,3-D] pyrimidine compounds | JAK1, JAK3, JAK2 | CHEK1 403/4885NOTUM 3508/4885AKT1 595/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.